Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

2.5K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
2.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Cancer Vaccines01:30

Cancer Vaccines

564
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
564

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structured reasoning failures compromise LLM interpretation of clinical oncology notes.

NPJ digital medicine·2026
Same author

B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cytoplasmic SNHG1 is enriched in prostate cancer stress granules.

Functional & integrative genomics·2026
Same author

Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors.

Cancer immunology research·2026
Same author

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

JCO precision oncology·2025
Same author

Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes.

Prostate cancer and prostatic diseases·2025
Same journal

Corrigendum to "Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice" [Cancer Lett. (2022) 31 529 53-69].

Cancer letters·2026
Same journal

Corrigendum to "PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer" [Cancer Lett. 598 (2024) 217112].

Cancer letters·2026
Same journal

Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers.

Cancer letters·2026
Same journal

Transcriptomic-based molecular classification of ampullary adenocarcinoma.

Cancer letters·2026
Same journal

Corrigendum to "LRH1 promotes pancreatic cancer metastasis" [Cancer Lett. (2014) 24 350 (1-2) 15-24].

Cancer letters·2026
Same journal

Corrigendum to "Histone deacetylase inhibitors upregulate Snail via Smad2/3phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells" [Cancer Lett. 420 (2018) 1-13].

Cancer letters·2026
See all related articles

Related Experiment Video

Updated: Oct 17, 2025

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

16.0K

Prostate cancer dormancy and recurrence.

Frank C Cackowski1, Elisabeth I Heath1

  • 1Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI, USA.

Cancer Letters
|October 8, 2021
PubMed
Summary
This summary is machine-generated.

Prostate cancer can enter a dormant state, evading treatment and recurring years later. Understanding dormant tumor cells in sites like bone marrow is key to preventing late recurrences.

Keywords:
Adjuvant therapyDormancyMetastasisProstate cancerQuiescenceRecurrence

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Related Experiment Videos

Last Updated: Oct 17, 2025

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

16.0K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Area of Science:

  • Oncology
  • Cancer Biology

Background:

  • Prostate cancer exhibits unique dormancy, recurring years after initial treatment.
  • Dormant tumor cells are found in bone marrow, lymph nodes, and the prostate bed.
  • Dormancy can be cellular (quiescent G0 phase) or tumor mass (proliferation/death balance).

Purpose of the Study:

  • To explore the mechanisms of prostate cancer cell dormancy.
  • To identify key signaling pathways and factors involved in dormancy induction.
  • To discuss implications for preventing late cancer recurrence.

Main Methods:

  • Review of existing literature on prostate cancer dormancy.
  • Analysis of signaling pathways (TGF-β2, BMP-7, GAS6, Wnt-5a) and transcription factors (SOX2, NANOG).
  • Discussion of cellular dormancy mechanisms including p38 MAPK and epigenetic modifications.

Main Results:

  • Prostate cancer cells respond to microenvironmental signals to induce dormancy.
  • Specific signaling pathways and transcription factors (SOX2, NANOG) are implicated in dormancy.
  • Histone modification is suggested as an epigenetic mechanism affecting dormancy.

Conclusions:

  • Understanding dormancy mechanisms is crucial for preventing late prostate cancer recurrence.
  • Targeting dormancy pathways may offer future therapeutic strategies.
  • Adjuvant therapies like radiation and androgen deprivation show modest success, with future improvements anticipated.